Video content above is prompted by the following: What are the main unmet needs for recurrent C difficile infections and how do you see the field evolving in the future?

EP: 12.Common Comorbidities Associated With Recurrent C Difficile Infections ...

A new study shows that oral fecal microbiota transplantation (FMT) is a feasible and safe addition to preventing graft-versus ...

Against that backdrop, the shortlisting of Astellas Pharma's C. diff treatment Dificlir (fidaxomicin) for the UK Prix Galien Innovative Product Award, reflects the critical need for additional ...

The use of fecal microbiota, live-jslm (RBL; REBYOTA®) in the prevention of recurrent Clostridioides difficile infection ...

Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases, today announced the publication of additional results from ...

Patients suffering from a recurrent infection with the C difficile bacteria have benefited from a microbiome treatment from Rebiotix. The results from the open label phase 2 trial confirm that ...

C. difficile spores are highly resistant to desiccation, chemicals and extreme temperature. Spores frequently contaminate the environment around patients with CDI, potentially persisting for ...

The evidence base on aetiology and treatment was small ... treatment facilities in St Louis. Mikton C. Grounds A. 2007 Vignette 1 (BPD): no sig diff in diagnosis PD. Vignette 2 (ASPD): More ...

A new study shows that oral fecal microbiota transplantation (FMT) is a feasible and safe addition to preventing graft-versus-host disease in patients undergoing stem cell transplantation for blood ...